|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Pediatric Neuro-Oncology |
Baylor College of Medicine, Houston, TX 77030 [D.H.M.]; School of Medicine, State University of New York, Buffalo, NY 14222 [M.E.C., P.K.D.]; Duke University Medical Center, Durham, NC 27710 [H.S.F.]; Statistical Office, University of Florida, Gainesville, FL 32601 [J.L.K.]; St. Vincent Hospital, Green Bay, WI 54301 [L.G.]; St. Jude Children's Research Hospital, Memphis, TN 38101 [J.W.L., L.E.K.]; and Children's Hospital and Health Center, San Diego, CA 92123 [H.E.J.]
2 Address reprint requests to Pediatric Oncology Group, Operations Office, 645 N. Michigan Ave., Suite 910, Chicago, IL 60611. Address correspondence to Donald H. Mahoney, Jr., Pediatric Oncology, MC 3-3320, Baylor College of Medicine, 6621 Fannin St., Houston, TX 77030.
Abstract
The Pediatric Oncology Group conducted a phase II study to evaluate the activity of carboplatin in children 5 years or younger with progressive optic pathway tumors (OPTs). Of the 51 patients accrued to this study, 1 was not eligible because the child was older than 6 years. Fifty patients were eligible and had either neuro-imaging or symptomatic evidence of progressive OPTs. Twenty-one of 50 had evidence of neurofibromatosis type I (NF-1). Therapy consisted of carboplatin 560 mg/m2 at 4-week intervals. Patients with stable disease or better after two courses were continued on therapy for 18 months or until progressive disease. Of the 50 eligible children, 39 had stable disease or better, and 34 completed the 18-month therapy. Our data are sufficient to conclude that the proportion of objective responses (complete, partial, or minor response or stable disease) exceeded 30% (P < 0.00001), and the approximate 95% confidence interval estimate of the objective response rate was 0.665 to 0.895. Twenty-one patients went off protocol because of progressive disease. Fifteen patients progressed during the 18-month therapy, and 6 patients progressed after completing therapy. Six children died with progressive disease. Major toxicities were neutropenia and thrombocytopenia, and 3 children experienced allergic reactions. Carboplatin is active and safe for the treatment of young children with progressive OPTs. The addition of other potentially active drugs may further increase the event-free survival for these children.
References
Alshail, E., Rutka, J.T., Becker, L.E., and Hoffman, H.J. (1997) Optic chiasmatic-hypothalamic glioma. Brain. Pathol. 7,799 -806.[ISI][Medline]
Alvord, E.C., Jr., and Lofton, S. (1988) Gliomas of the optic nerve or chiasm. J. Neurosurg. 68, 85-98.[Medline]
Brauner, R., Malandry, F., Rappaport, R., Zucker, J.M., Kalifa, C., Pierre-Kahn, A., Bataini, P., and Dufier, J.L. (1990) Growth and endocrine disorders in optic glioma. Eur. J. Pediatr. 149,825 -828.[CrossRef][Medline]
Chamberlain, M.C., and Grafe, M.R. (1995) Recurrent
chiasmatic-hypothalamic glioma treated with oral etoposide. J.
Clin. Oncol. 13,2072
-2076.
Charrow, J., Listernick, R., Greenwald, M.J., Das, L., and Radkowski, M.A. (1993) Carboplatin-induced regression of an optic pathway tumor in a child with neurofibromatosis. Med. Pediatr. Oncol. 21,680 -684.[Medline]
Davis, P.C., Hoffman, J.C., Jr., Pearl, G.S., and Baum, I.F. (1986) CT evaluation of effects of cranial radiation therapy in children. Am. J. Neuroradiol. 7, 639-644.
Duffner, P.K., and Cohen, M.E. (1991) Long-term consequences of CNS treatment for childhood cancer. Part II: Clinical consequences. Pediatr. Neurol. 7, 237-242.[Medline]
Dutton, J.J. (1994) Gliomas of the anterior visual pathway: Major review. Surv. Ophthalmol. 38,427 -452.[CrossRef][ISI][Medline]
Flickinger, J.C., Torres, C., and Deutsch, M. (1988) Management of low grade gliomas of the optic nerve and chiasm. Cancer 61,635 -642.[CrossRef][Medline]
Friedman, H.S., Krischer, J.P., Burger, P., Oakes, W.J., Hockenberger, B., Weiner, M.D., Falletta, J.M., Norris, D., Ragab, A.H., Mahoney, D.H., Jr., Whitehead, M.V., and Kun, L.E. (1992) Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: A Pediatric Oncology Group randomized phase II study. J. Clin. Oncol. 10,249 -256.[Medline]
Grill, J., Couanet, D., Cappelli, C., Habrand, J.L., Rodriguez, D., Sainte-Rose, C., and Kalifa, C. (1999) Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma. Ann. Neurol. 45,393 -396.[CrossRef][ISI][Medline]
Hoffman, H.J., Humphrey, R.P., Drake, J.M., Rutka, J.J., Becker, L.E., Jenkin, D., and Greenberg, M. (1993) Optic pathway/hypothalamic gliomas: A dilemma in management. Pediatr. Neursurg. 19,186 -195.
Horwich, A., and Bloom, H.J.G. (1985) Optic gliomas: Radiation therapy and prognosis. Int. J. Radiat. Oncol. Biol. Phys. 11,1067 -1079.[Medline]
Housepian, E.M., and Chi, T.L. (1993) Neurofibromatosis and optic pathway gliomas. J. Neurooncol. 15,51 -55.[Medline]
Hoyt, W.F., and Baghdassarian, S.A. (1969) Optic gliomas of childhood: Natural history and rationale for conservative management. Br. J. Ophthalmol. 53,793 -798.
Imes, R.K., and Hoyt, W.F. (1986) Childhood chiasmal
gliomas:Update on the fate of patients in the 1969 San Francisco Study.
Br. J. Ophthalmol. 70,179
-182.
Jenkin, D., Angyalfi, S., Becker, L., Berry, M., Buncic, R., Chan, H., Doherty, M., Drake, J., Greenberg, M., Hendrick, B., Hoffman, H., Humpheys, R., and Weitzman, S. (1993) Optic glioma in children: Surveillance, resection, or radiation? Int. J. Radiat. Oncol. Biol. Phys. 25,215 -225.[ISI][Medline]
Kaplan, E.L., and Meier, P. (1958) Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53,457 -481.[CrossRef][ISI]
Kovalic, J.J., Grigsby, P.W., Shepard, M.J., Fineberg, B.B., and Thomas, P.R. (1990) Radiation therapy for gliomas of the optic nerve and chiasm. Int. J. Radiat. Oncol. Biol. Phys. 18,927 -932.[Medline]
Lewis, R.A., Gerson, L.P., Axelson, K.A., Riccardi, V.M., and Whitford, R.P. (1984) von Recklinghausen neurofibromatosis. II. Incidence of optic gliomata. Ophthalmology 91,929 -935.[ISI][Medline]
Listernick, R., Charrow, J., Greenwald, M.J., and Esterly, N.B. (1989) Optic gliomas in children with neurofibromatosis type 1. J. Pediatr. 114,788 -792.[CrossRef][Medline]
Listernick, R., Charrow, J., Greenwald, M., and Mets, M. (1994) Natural history of optic pathway tumors in children with neurofibromatosis type 1: A longitudinal study. J. Pediatr. 125,63 -66.[CrossRef][ISI][Medline]
Listernick, R., Louis, D.N., Packer, R.J., and Gutmann, D.H. (1997) Optic pathway gliomas in children with neurofibromatosis 1: Consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann. Neurol. 41,143 -149.[CrossRef][ISI][Medline]
Lund, A.M., and Skovby, F. (1991) Optic gliomas in children with neurofibromatosis type 1. Eur. J. Pediatr. 150,835 -838.[CrossRef][ISI][Medline]
Moghrabi, A., Friedman, H.S., Burger, P.C., Tien, R., and Oakes, W.J. (1993) Carboplatin treatment of progressive optic pathway gliomas to delay radiotherapy. J. Neurosurg. 79,223 -227.[ISI][Medline]
Okuno, T., Prensky, A.L., and Gado, M. (1985) The moyamoya syndrome associated with irradiation of optic glioma in children: Report of 2 cases and review of the literature. Pediatr. Neurol. 1,311 -316.[CrossRef][Medline]
Packer, R.J., Lange, B., Ater, J., Nicholson, H.S., Allen, J.,
Walker, R., Prados, M., Jakacki, R., Reaman, G., Needles, M.N., Phillips,
P.C., Ryan, J., Boyett, J.M., Geyer, R., and Finlay, J. (1993)
Carboplatin and vincristine for recurrent and newly diagnosed low-grade
gliomas of childhood. J. Clin. Oncol.
11,850
-856.
Packer, R.J., Sutton, L.N., Bilanuk, L.T., Radcliffe, J., Rosenstock, J.G., Siegel, K.R., Bunin, G.R., Savino, P.J., Bruce, D.A., and Schut, L. (1988) Treatment of chiasmatic/hypothalamic gliomas of childhood with chemotherapy: An update. Ann. Neurol. 23, 79-85.[CrossRef][ISI][Medline]
Peto, R., Pike, M.C., Armitage, P., Breslow, N.E., Cox, D.R., Howard, S.V., Mantel, N., McPherson, K., Peto J., and Smith, P.G. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer 35,1 -39.[ISI][Medline]
Pierce, S.M., Barnes, P.D., Loef`er, J.S., McGinn, C., and Tarbell, N.J. (1990) Definitive radiation therapy in the management of symptomatic patients with optic glioma: Survival and long-term effects. Cancer 65,45 -52.[CrossRef][ISI][Medline]
Prados, M.D., Edwards, M.S.B., Rabbitt, J., Lamborn, K., Davis, R.L., and Levin, V.A. (1997) Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J. Neurooncol. 32,235 -241.[CrossRef][Medline]
Rush, J.A., Younge, B.R., Campbell, R.J., and MacCarty, C.S. (1982) Optic glioma: Long-term follow-up of 85 histopathologically verified cases. Ophthalmology 89,1213 -1219.[Medline]
Sayli, T., Cemeroglu, A.P., Tuncer, A.M., and Gurgey, A. (1993) Acute lymphoblastic leukemia following optic glioma treated by radiotherapy and surgery. Acta Pediatr. 82,327 -328.[Medline]
Wisoff, J.H., Abbott, R., and Epstein, F. (1990) Surgical management of exophytic chiasmatic hypothalamic tumors of childhood. J. Neurosurg. 73,661 -667.[Medline]
Wright, J.E., McDonald, W.I., and Call, N.B. (1980)
Management of optic nerve gliomas. Br. J. Ophthalmol.
64,545
-552.
Wright, J.E., McNabb, A.A., and McDonald, W.I. (1989)
Optic nerve glioma and the management of optic nerve tumours in the young.
Br. J. Ophthalmol. 73,967
-974.
This article has been cited by other articles:
|
|
 |
|
  S. R. Burzynski The Present State of Antineoplaston Research (1) Integr Cancer Ther, March 1, 2004; 3(1): 47 - 58. [Abstract] [PDF]
|
|
|
|
 |
|
 J. A. Quinn, D. A. Reardon, A. H. Friedman, J. N. Rich, J. H. Sampson, J. M. Provenzale, R. E. McLendon, S. Gururangan, D. D. Bigner, J. E. Herndon II, et al. Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma J. Clin. Oncol., February 15, 2003; 21(4): 646 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Massimino, F. Spreafico, G. Cefalo, R. Riccardi, J. D. Tesoro-Tess, L. Gandola, D. Riva, A. Ruggiero, L. Valentini, E. Mazza, et al. High Response Rate to Cisplatin/Etoposide Regimen in Childhood Low-Grade Glioma J. Clin. Oncol., October 15, 2002; 20(20): 4209 - 4216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gururangan, C. M. Cavazos, D. Ashley, J. E. Herndon II, C. S. Bruggers, A. Moghrabi, D. L. Scarcella, M. Watral, S. Tourt-Uhlig, D. Reardon, et al. Phase II Study of Carboplatin in Children With Progressive Low-Grade Gliomas J. Clin. Oncol., July 1, 2002; 20(13): 2951 - 2958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E.G. Hassall, A. E. Mitchell, and D. M. Ashley Carboplatin chemotherapy for progressive intramedullary spinal cord low-grade gliomas in children: Three case studies and a review of the literature Neuro-oncol, October 1, 2001; 3(4): 251 - 257. [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
